Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003646 · ClinicalTrials.gov registry record · Phase 2
Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma
A Phase 2 study, sponsored by Vical.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT00003646: Completed Phase 2 study, sponsored by Vical.
NCT00003646 is a Phase 2 study that has completed, run by Vical. The registered enrollment target is 78 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003646, a Phase 2 study, has completed, sponsored by Vical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have stage III or stage IV melanoma that has not responded to previous treatment.
Interventions
- DRUG allovectin-7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 1998-08 |
| Est. Completion | 2002-05 |
| Phase | Phase 2 |
What the finished NCT00003646 record still lists
NCT00003646 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 1 intervention - of which allovectin-7 is the first listed.
NCT00003646 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003646 about?
NCT00003646 is a clinical study titled "Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have stage III or stage IV melanoma that has not responded to previous ...
What is the current status of trial NCT00003646?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 1998-08. Estimated completion is 2002-05.
What interventions are being tested in trial NCT00003646?
The interventions under investigation include: allovectin-7 (DRUG).
Who is sponsoring clinical trial NCT00003646?
This trial is sponsored by Vical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003646's enrollment target sits among peer trials
78 884th of 2000 higher than 1,110 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia